Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New approach to cancer treatment shown to be highly effective

19.04.2005


Attacking novel S1P target eliminates cancerous tumors in some cases



An antibody developed by San Diego-based Lpath Therapeutics, Inc. could someday treat many of the deadliest solid and liquid tumors. This unique monoclonal antibody, called SphingomabTM, was tested in several animal models of human cancer and was shown to significantly retard cancer growth on a consistent basis; in some cases, it eliminated the tumor altogether.

According to Roger Sabbadini, Founder and Chief Scientific Officer of Lpath Therapeutics, the company has developed a monoclonal antibody against sphingosine-1-phosphate (S1P) and has validated S1P as a therapeutic target for cancer. Lpath is now preparing to seek FDA approval for human trials.


The results of two studies supporting this novel approach to cancer therapy were released at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, California on April 18. One of the studies was presented by Gordon Mills, M.D., Ph.D., of The University of Texas M. D. Anderson Cancer Center. Dr. Mills has pioneered the study of the important role that lysolipids (like S1P) play in the growth and metastasis of cancer cells.

According to Dr. Mills, the most deadly, multi-resistant cancers--including lung, breast, melanoma, and ovarian cancers--responded well to the SphingomabTM approach of targeting S1P. The SphingomabTM treatment not only blocked the effects of S1P on the cancer cells themselves, but also prevented tumor angiogenesis, which is the formation of new blood vessels that feed the growing tumor.

Lpath Therapeutics believes that interfering with sphingolipid function can result in clinically relevant therapeutic outcomes. Sphingolipids are structural and multifunctional lipid mediators largely involved in signaling activities required for normal cellular function. However, sphingolipids can become dysfunctional and thereby contribute directly to the pathophysiology of cancer, inflammation, and cardiovascular diseases.

Lpath Therapeutics, Inc. was founded in 1998 at San Diego State University based on the work of Dr. Sabbadini in the area of sphingolipid research. Lpath initially focused on the role of sphingolipids in cardiovascular disease and later expanded its research around sphingolipids to treat a broad range of diseases, including cancer.

Dr. Roger Sabbadini | EurekAlert!
Further information:
http://www.Lpath.com

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

Im Focus: Repairing defects in fiber-reinforced plastics more efficiently

Fiber-reinforced plastics (FRP) are frequently used in the aeronautic and automobile industry. However, the repair of workpieces made of these composite materials is often less profitable than exchanging the part. In order to increase the lifetime of FRP parts and to make them more eco-efficient, the Laser Zentrum Hannover e.V. (LZH) and the Apodius GmbH want to combine a new measuring device for fiber layer orientation with an innovative laser-based repair process.

Defects in FRP pieces may be production or operation-related. Whether or not repair is cost-effective depends on the geometry of the defective area, the tools...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Multiregional brain on a chip

16.01.2017 | Power and Electrical Engineering

New technology enables 5-D imaging in live animals, humans

16.01.2017 | Information Technology

Researchers develop environmentally friendly soy air filter

16.01.2017 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>